November 28, 2017

On Omeros

SA has a two part series on Omeros, a small cap biotech that has two major products in the pipeline that could result in significant upside for the company.  Part 1 is here and part 2 is here.

The Fool is bullish on them as well, calling the company the "best buy in biotech."

No comments: